Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor Epitopes

通过阻断多个 CCR2 趋化因子受体表位将巨噬细胞极化为肿瘤抑制因子

基本信息

  • 批准号:
    9973323
  • 负责人:
  • 金额:
    $ 35.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-02-01 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Despite the important role of the tumor stroma in cancer progression, the vast majority of anticancer therapies target cancer cells and not the tumor microenvironment. A novel drug delivery approach that not only target tumor cells but also the inflammatory cells would be highly desirable. Here we propose to develop a delivery platform that builds on our recent work designing single chain variable fragment antibodies that both inhibit inflammatory monocyte migration to tumors and polarize macrophages towards the tumoricidal M1 phenotype by hijacking the CCL2/CCR2 pathway. This approach capitalizes on antibody binding specificity but exploits CCR2 receptor structure and function to improve therapeutic efficacy. We hypothesize that simultaneous targeting of multiple CCR2 epitopes will mediate a synergistic drug effect and inhibit tumor growth and metastasis by inducing M1 macrophage polarization and reducing macrophage migration. Our protein delivery approach capitalizes on both the targeting specificity of antibody fragments and also their ability to induce or modify downstream signaling. Thus, the antibody fragments will serve both as a delivery vehicle and therapeutic drug and have the potential to minimize carrier-induced toxicity. The specific aims of this proposal are to (1) synthesize a modular CCR2-targeting zip-ligand system for macrophage polarization and establish its mechanism of action; (2) assess the effects of multi-epitope CCR2-targeting constructs on macrophage polarization, tumor growth, and metastasis in a triple-negative breast cancer (TNBC) mouse model; and (3) evaluate the therapeutic effects of multi-epitope CCR2 targeting in combination with (a) anti-PD-1 blockade and (b) other therapeutics in a mouse model of TNBC, a subtype with particularly poor clinical outcomes and limited treatment options. Upon successful completion, this project will establish a new delivery concept to modify downstream signaling and modulate cellular phenotypes.
项目摘要 尽管肿瘤间质在癌症进展中发挥着重要作用,但绝大多数抗癌疗法 靶向癌细胞,而不是肿瘤微环境。一种新的药物递送方法,不仅靶向 肿瘤细胞以及炎性细胞将是高度期望的。在这里,我们建议开发一个交付 该平台建立在我们最近设计单链可变片段抗体的工作基础上, 炎性单核细胞迁移至肿瘤和巨噬细胞向杀肿瘤M1表型迁移 通过劫持CCL 2/CCR 2通路。这种方法利用了抗体结合特异性,但利用了 CCR 2受体的结构和功能,以提高治疗效果。我们假设同时 靶向多个CCR 2表位将介导协同药物效应并抑制肿瘤生长和转移 通过诱导M1巨噬细胞极化和减少巨噬细胞迁移。我们的蛋白质递送方法 利用抗体片段的靶向特异性以及它们诱导或修饰 下行信号。因此,抗体片段将用作递送载体和治疗药物 并且具有使载体诱导的毒性最小化的潜力。本提案的具体目标是:(1)综合 用于巨噬细胞极化的模块化CCR 2靶向zip-ligand系统,并建立其作用机制; (2)评估多表位CCR 2靶向构建体对巨噬细胞极化,肿瘤生长, 三阴性乳腺癌(TNBC)小鼠模型中的转移;和(3)评估治疗效果 多表位CCR 2靶向与(a)抗PD-1阻断剂和(B)其它治疗剂组合在小鼠中的应用 TNBC是一种临床结果特别差且治疗选择有限的亚型。一旦成功 完成后,该项目将建立一个新的交付概念,以修改下游信令和调制 细胞表型

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Juliane Nguyen其他文献

Juliane Nguyen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Juliane Nguyen', 18)}}的其他基金

Developing genetically encodable probes for multimodal tracking of exosomal RNA cargo
开发用于外泌体 RNA 货物多模式追踪的基因可编码探针
  • 批准号:
    10681827
  • 财政年份:
    2023
  • 资助金额:
    $ 35.2万
  • 项目类别:
Engineering a cross-linked cellular network for cardiac repair
设计用于心脏修复的交联细胞网络
  • 批准号:
    10539723
  • 财政年份:
    2022
  • 资助金额:
    $ 35.2万
  • 项目类别:
Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor Epitopes
通过阻断多个 CCR2 趋化因子受体表位将巨噬细胞极化为肿瘤抑制因子
  • 批准号:
    10380283
  • 财政年份:
    2021
  • 资助金额:
    $ 35.2万
  • 项目类别:
Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor Epitopes
通过阻断多个 CCR2 趋化因子受体表位将巨噬细胞极化为肿瘤抑制因子
  • 批准号:
    10328882
  • 财政年份:
    2020
  • 资助金额:
    $ 35.2万
  • 项目类别:
Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor Epitopes
通过阻断多个 CCR2 趋化因子受体表位将巨噬细胞极化为肿瘤抑制因子
  • 批准号:
    10737843
  • 财政年份:
    2020
  • 资助金额:
    $ 35.2万
  • 项目类别:
Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor Epitopes
通过阻断多个 CCR2 趋化因子受体表位将巨噬细胞极化为肿瘤抑制因子
  • 批准号:
    10524148
  • 财政年份:
    2020
  • 资助金额:
    $ 35.2万
  • 项目类别:
Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor Epitopes
通过阻断多个 CCR2 趋化因子受体表位将巨噬细胞极化为肿瘤抑制因子
  • 批准号:
    10559551
  • 财政年份:
    2020
  • 资助金额:
    $ 35.2万
  • 项目类别:
Self-replicating RNA-nanoplexes for programming monocytes to regenerate the heart
用于编程单核细胞以再生心脏的自我复制RNA纳米复合物
  • 批准号:
    8968584
  • 财政年份:
    2015
  • 资助金额:
    $ 35.2万
  • 项目类别:
Self-replicating RNA-nanoplexes for programming monocytes to regenerate the heart
用于编程单核细胞以再生心脏的自我复制RNA纳米复合物
  • 批准号:
    9105404
  • 财政年份:
    2015
  • 资助金额:
    $ 35.2万
  • 项目类别:
Maximizing small RNA delivery with signaling pepitdes
通过信号肽最大化小 RNA 递送
  • 批准号:
    9145216
  • 财政年份:
    2015
  • 资助金额:
    $ 35.2万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 35.2万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 35.2万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 35.2万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.2万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 35.2万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 35.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 35.2万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 35.2万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 35.2万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 35.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了